Welcome to the new Gustave Roussy website
A new website designed to offer you a simpler, clearer, and more intuitive experience. Patients, caregivers, healthcare professionals, and donors: find information, news, and services more easily.
Paediatric cancer, innovating today for better treatment tomorrow
More cures and better cures. With the dual purpose of improving survival and reducing sequelae, Gustave Roussy is contributing to ambitious research programmes in Paediatric Oncology and to the management of young adults.
Published on
Changed on
More cures and better cures. With the dual purpose of improving survival and reducing sequelae, Gustave Roussy is contributing to ambitious research programmes in Paediatric Oncology and to the management of young adults.
Two novel trials devoted to children and adolescents
Today, less than 10% of young patients in Europe in relapse have access to a new drug. For Professor Vassal, Director of Clinical Research, “The issue is to speed up access to novel treatments for children and adolescents with treatment failure.” To achieve this, the Institute is embarking on two new clinical trials. Since late December 2015, MAPPYACTS has been determining the molecular portrait of 300 young patients. The ImmunoACTS study is integrated with this project and seeks to characterize the immune cells which are present. The long-term objective is to develop bespoke drugs able to block the immune cells which are responsible for the observed resistance to treatment. The Acsé-eSMART trial, which will commence shortly, will test several novel agents in 250 children. It is hoped over 2 years to double the number of new drugs tailored to the defined molecular portraits.
A long-term follow-up clinic
Whereas progress in recent decades means that 80% of young patients can be cured, almost 2/3 of them run the risk of sequelae. Assessing in adult life the consequences of treatments administered to patients in childhood is also a way of improving the management of children who are being treated today. Gustave Roussy has, therefore, established a Long-Term Follow-up Clinic to inform patients and to detect and treat late complications in adults whose childhood cancer was cured.
Last news
-
Breast Cancer: Gustave Roussy Ranked No. 1 in France for Breast Surgery and Breast Reconstruction
On the occasion of Breast Cancer Awareness Month, the 2025 data from Visuchir, the national surgical activity monitoring tool of the French Health Insurance system, places Gustave Roussy in first position for both breast surgery and breast reconstruction. Beyond this ranking, these figures highlight that reconstruction is now an integral part of breast cancer treatment. It is considered at every stage of care: from tumor removal surgery, whether lumpectomy or mastectomy, through to the post-cancer period, helping to restore the body and support women in regaining their physical integrity and quality of life.
-
Newsweek Ranking: Gustave Roussy Named Europe’s Leading Cancer Centre and Third Best Worldwide
The 2027 edition of Newsweek’s World's Best Specialized Hospitals ranking once again recognises Gustave Roussy as the leading cancer centre in France and Europe, and the third best worldwide. This distinction highlights the excellence of the Institute’s care and research, as well as the daily commitment of all its professionals.
-
Living with and beyond cancer: the promises and challenges of digital health
In a Viewpoint article published in The Lancet Digital Health, Drs Ines Vaz-Luis and Maria Alice Franzoi, together with Emmanuel Mussault, a patient partner at the PRISM University Hospital Institute, examine the role that digital tools can play in supporting people living with and beyond cancer. Their central message is that these technologies can support more personalised and accessible care, but their value depends primarily on how they are integrated into care pathways, the human support provided, their ability to address individual needs and their evaluation in real-world settings.
-
Gustave Roussy and The Lancet launch an international lecture series on innovations transforming cancer care
The inaugural lecture in the “Lecture Series on Cancer Breakthroughs” will take place on Friday 18 September at 5:00 pm. It will be delivered by Professor Timothy R. Rebbeck, a leading cancer prevention specialist at Harvard University and the Dana-Farber Cancer Institute.
